Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease.
Carella
Angelo Michele
AM
Biasco
Samantha
S
Nati
Sandro
S
Congiu
Angela
A
Lerma
Enrica
E
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D000069283:Rituximab; D013256:Steroids / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D013256:Steroids; D000069283:Rituximab